Dazodalibep + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren's Syndrome (SS)
Conditions
Sjögren's Syndrome (SS)
Trial Timeline
Apr 8, 2024 → Dec 17, 2026
NCT ID
NCT06245408About Dazodalibep + Placebo
Dazodalibep + Placebo is a phase 3 stage product being developed by Amgen for Sjögren's Syndrome (SS). The current trial status is active. This product is registered under clinical trial identifier NCT06245408. Target conditions include Sjögren's Syndrome (SS).
What happened to similar drugs?
0 of 7 similar drugs in Sjögren's Syndrome (SS) were approved
Approved (0) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06245408 | Phase 3 | Active |
| NCT06104124 | Phase 3 | Active |
Competing Products
20 competing products in Sjögren's Syndrome (SS)